This study is testing a new oral medication called azenosertib against standard chemotherapy options for women with platinum-resistant high-grade serous ovarian, primary peritoneal, or fallopian tube cancers. These cancers have stopped responding to platinum-based chemotherapy. Researchers want to see if azenosertib is more effective and safer than chemotherapy. You may be able to join if you are a woman aged 18 or older with one of these cancers, and your tumor shows a specific protein called Cyclin E1. The main goal is to see how long people live without their cancer growing (progression-free survival). The study is currently recruiting about 420 participants, but its exact status is unclear.

Study design

This is a randomized Phase 3 study, meaning participants will be assigned by chance to receive either azenosertib or one of several standard chemotherapy drugs. The study plans to enroll 420 participants.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

Participants will be followed for progression-free survival for up to approximately 24 months from the enrollment of the last subject.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.